Editorial, J Regen Med Vol: 9 Issue: 1
Regenerative Medicine 2020 Editorial Note
Alex F. Chen*
Director of VA Vascular Surgery Research University of Pittsburgh, USA
*Corresponding Author: Dr. Alex F. Chen
Director of VA Vascular Surgery Research, University of Pittsburgh, USA
E-mail: alexchan@ottawaheart.ca
Received: April 25, 2020 Accepted: May 03, 2020 Published: May 10, 2020
Citation: Chen AF (2020) Regenerative Medicine 2020 Editorial Note. J Regen Med 9:1. doi: 10.37532/jrgm.2020.9(1).e158
Abstract
Journal of Regenerative Medicine (JRGM) is a peer-reviewed scholarly journal and aims to publish the most varied and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas Medicine and making them available online freely without any restrictions or any other subscriptions to researchers worldwide.
Keywords: Cellular Therapies Diagnostics and Imaging Ethical and Legal Issues Gene Therapies
Journal of Regenerative Medicine (JRGM) is a peer-reviewed scholarly journal and aims to publish the most varied and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas Medicine and making them available online freely without any restrictions or any other subscriptions to researchers worldwide.
The Journal is using Editorial Tracking System for tracking and quality of review process. Editorial Tracking is an online manuscript submission, review and tracking system. Review processing is performed by the editorial board members of Journal Regenerative Medicine or outside experts; at least two independent reviewer’s approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process
For the last 12 years, published papers has been under the strong and able leadership of our Editor-in-Chief’s DR.Ian McNiece and Editor’s Dr.Chandra Kothapalli, Dr.Farid Menaaand Dr.Leonardo Ricotti.
Especially, the publication office is thankful to Dr. Ian Mc Niece (Editor-in-Chief), also he is working as a Professor, Professor Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, United States for his continuous support and dedication towards the journal
The Journal Impact Factor: 1.01 ISSN: 2327-4581 is the ratio of the number of citations achieved in the year 2019 based on Google Search and Google Scholar Citations to the total number of articles published in the last two years i.e. in 2017 and 2018. Impact factor measures the quality of the Journal.
Scope of Journal
The scope includes study and recent advancements of research developments. Journal of Regenerative Medicine focuses on the topics include regenerative medicine therapies, stem cell applications, tissue engineering, gene and cell therapies, translational medicine and tissue regeneration.
Stem Cells: Stem cells are undifferentiated cells, that can differentiate into specialized cells and can divide to produce more stem cells. They are found in multicellular organisms.
Gene Therapy: Gene Therapyis a medical field which focuses on the utilization of the therapeutic delivery of nucleic acid into a patient’s cells as a drug to treat disease. It is thought to be able to cure many genetic disorders or treat them over time.
The Journal aims to publish most reliable information on the discoveries and contemporary revelations in the mode of original articles, review articles, case reports, short communications, etc.
The respective manuscript which is accepted in preliminary quality check will be assigned to the Editor Board Member (Action Manager), the Action Editor can only make decision on the manuscript for the entire review process, later the manuscript will be assigned to potential reviewers to make a critical review on the paper. Upon the critical review report by the potential reviewers, the Action Managers will take the decision to ACCEPT/REVISE/REJECT:
Benefits for the Authors
• Within 40-day rapid review process with global peer-review standards.
• Timeline of processing from Submission to Publication is 45 days.
• Manuscript will be published within 7days of acceptance. Submission: quick review processing.
You can submit your manuscript at Online Manuscript Submission System or send us an e-mail attachment to the Editorial Office at regenmed@journalres.org
Applied strategies
We have applied many strategies
• Contacting Authors through Mobile (WhatsApp) phones for speedy response
• Sending Call for papers for the eminent in the field
• Approaching the Editors suggested eminent
• Approaching potential reviewers for the Call for papers
Upcoming with new Strategies for 2020
• We strive to improve readers for the published respective article in various social media platforms like Twitter, Linked in, etc.
• We are approaching core Laboratories, research institutes, investigation labs and departmental Universities for call for papers as well as related journals.
• We are sending timely Call for papers for the respective countries according to their time line.
• We are also available to the authors through live chat and WhatsApp to respond fast.
Conclusion
We believe this is a necessary practice that will foster the next generation of commentators and improve the study of the conduct of scientific publication